Secukinumab (Cosentyx®) for Ankylosing Spondylitis

Assessment Status Rapid Review Complete
Drug Secukinumab
Brand Cosentyx®
Indication For the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy
Assessment Process
Rapid review commissioned 02/12/2015
Rapid review completed 14/12/2015
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended

The HSE has approved reimbursement following confidential price negotiations.